Ophthalmology Clinic, Faculty of Medicine, Cairo University, Giza, Egypt.
J Ocul Pharmacol Ther. 2009 Dec;25(6):513-7. doi: 10.1089/jop.2009.0056.
We studied the effect of an intracameral bevacizumab injection on the corneal endothelium and iris neovessels (INV).
Ten eyes were studied in 10 patients with an average age of 52.1 +/- 13.17 years. Patients underwent intracameral bevacizumab injections at a concentration of 1.25 mg/0.05 mL. Intraocular pressure, best-corrected visual acuity, gonioscopy, neovascular membrane extent, anterior segment photography, iris fluorescein angiography, pachymetry, and specular microscopy were recorded preoperatively and postoperatively.
The minimum follow-up period was 4 months. INVs started to regress within the first 2 days after the injection and regressed completely by the end of the fourth week. Reduction in INV leakage started 1 week after injection, and resolved in 8 eyes (80%) by the end of the fourth week. Intraocular pressure dropped significantly from 17.8 +/- 4.8 mmHg to 16.6 +/- 2.8 mmHg over 4 weeks. The mean endothelial cell loss was 3.95% +/- 6.78%.
An intracameral bevacizumab injection proved to be safe for corneal endothelial cells.
我们研究了前房内注射贝伐单抗对角膜内皮和虹膜新生血管（INV）的影响。
10 例患者（10 只眼）的平均年龄为 52.1 +/- 13.17 岁。患者接受浓度为 1.25 mg/0.05 mL 的前房内贝伐单抗注射。记录术前和术后眼压、最佳矫正视力、房角镜检查、新生血管膜范围、眼前段照相、虹膜荧光血管造影、角膜厚度和共焦显微镜检查结果。
最短随访时间为 4 个月。INV 在注射后第 2 天开始消退，第 4 周末完全消退。INV 渗漏减少在注射后 1 周开始，并在第 4 周末 8 只眼（80%）缓解。眼压在 4 周内从 17.8 +/- 4.8mmHg 降至 16.6 +/- 2.8mmHg。平均内皮细胞丢失率为 3.95% +/- 6.78%。
前房内注射贝伐单抗对角膜内皮细胞安全有效。
